The increase in price target from $400 to $575 by Oppenheimer indicates a strong positive sentiment towards United Therapeutics' future performance. The 'Outperform' rating suggests that the stock is expected to perform better than the market average, which is likely to attract investor interest and potentially drive the stock price up in the short term.